Physician
Florida Cancer Specialists & Research Institute, LLC
Florida Cancer Specialists & Research Institute, LLC was paid $63.34M by Medicaid between Jan 2018 and Dec 2024, across 111 billing codes. Its largest line is 36415, Collection of venous blood by venipuncture — 32% of everything it billed.
33Billing provider infoFLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC
CAPE CORAL, FL 33914
CAPE CORAL, FL 33914
33aNPI1760590962assigned 08/28/2006
33bProvider typeTherapeutic Radiology Physician
28Total paid$63.34M
24GClaims1,220,223
24DCodes billed111
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Therapeutic Radiology Physician providers in Florida
Rank by total paid#1 of 8
Median peer was paid$4K
This provider vs. median14,765×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official GORDAN, LUCIO controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 31,660 | $85K | |
| 2019 | 165,831 | $20.11M | |
| 2020 | 208,043 | $25.79M | |
| 2021 | 185,144 | $12.67M | |
| 2022 | 196,947 | $1.64M | |
| 2023 | 273,398 | $1.93M | |
| 2024incomplete | 159,200 | $1.11M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 36415 | Collection of venous blood by venipuncture | 32% | 262,891 | 178,751 | $20.01M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 29% | 364,348 | 236,810 | $18.11M |
| 80053 | Comprehensive metabolic panel | 15% | 89,674 | 64,558 | $9.48M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 8.2% | 129,440 | 96,303 | $5.17M |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 4.3% | 13,756 | 7,621 | $2.72M |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.6% | 53,546 | 33,472 | $2.26M |
| 78815 | Positron emission tomography (PET) for limited area imaging | 2.2% | 4,547 | 3,699 | $1.38M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 1.4% | 41,257 | 34,227 | $889K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 14,418 | 8,928 | $706K |
| 96367 | <1% | 3,469 | 1,862 | $461K | |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 5,787 | 4,977 | $445K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 7,427 | 6,380 | $340K |
99 more codes
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 5,804 | $168K |
| J1756 | Injection, iron sucrose, 1 mg | <1% | 3,555 | $146K |
| 99233 | Hospital visit by a doctor, follow-up day (complex) | <1% | 2,918 | $141K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,650 | $133K |
| A9552 | Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | <1% | 4,201 | $121K |
| 82728 | <1% | 22,665 | $118K | |
| 82378 | <1% | 5,921 | $107K | |
| 99223 | Prolong inpt eval add15 m | <1% | 890 | $53K |
| 82607 | <1% | 8,972 | $46K | |
| 88184 | <1% | 245 | $43K | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 16,702 | $42K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 1,132 | $33K |
| 83615 | <1% | 6,625 | $16K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 9,119 | $15K |
| 99222 | Initial hospital care, per day, moderate complexity | <1% | 310 | $14K |
| 83550 | <1% | 12,035 | $13K | |
| 99255 | <1% | 188 | $12K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 198 | $11K |
| 86334 | <1% | 12,407 | $10K | |
| 83540 | <1% | 20,610 | $10K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,635 | $9K |
| 88189 | <1% | 286 | $7K | |
| J1750 | Injection, iron dextran, 50 mg | <1% | 29 | $7K |
| 82784 | <1% | 2,460 | $6K | |
| 86300 | <1% | 3,357 | $6K | |
| 84466 | <1% | 5,919 | $6K | |
| 84165 | <1% | 16,160 | $5K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 106 | $5K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 276 | $5K |
| 77300 | <1% | 16 | $5K | |
| 99205 | Prolong outpt/office vis | <1% | 68 | $4K |
| 71250 | <1% | 132 | $4K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,177 | $3K |
| 77427 | <1% | 34 | $3K | |
| 82746 | <1% | 5,209 | $3K | |
| 88185 | <1% | 243 | $3K | |
| 88237 | <1% | 59 | $3K | |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | <1% | 15 | $3K |
| 70491 | <1% | 28 | $3K | |
| 83521 | <1% | 5,605 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,550 | $2K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 68 | $2K |
| 86304 | <1% | 747 | $2K | |
| 84153 | <1% | 1,232 | $2K | |
| 99254 | <1% | 34 | $2K | |
| 86301 | <1% | 666 | $2K | |
| 88374 | <1% | 39 | $1K | |
| 77014 | <1% | 23 | $1K | |
| 99231 | Subsequent hospital care, per day, straightforward or low complexity | <1% | 58 | $1K |
| 96523 | <1% | 159 | $1K | |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | <1% | 71 | $1K |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 2,833 | $1K |
| 83020 | <1% | 951 | $1K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 28 | $1K |
| 99245 | <1% | 13 | $974.98 | |
| 99244 | Office or other outpatient consultation, moderate to high complexity | <1% | 13 | $918.09 |
| 82668 | <1% | 632 | $873.54 | |
| 83735 | <1% | 4,156 | $781.84 | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 68 | $746.04 |
| 82533 | <1% | 1,002 | $703.42 | |
| 99252 | <1% | 13 | $676.00 | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 43 | $634.67 |
| 86704 | <1% | 887 | $565.73 | |
| 82232 | <1% | 565 | $542.35 | |
| 86317 | <1% | 827 | $522.16 | |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 71 | $517.13 |
| 83010 | <1% | 849 | $460.95 | |
| 88264 | <1% | 38 | $457.86 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 563 | $420.42 |
| 87340 | <1% | 899 | $331.20 | |
| 88342 | <1% | 24 | $250.69 | |
| 88313 | <1% | 26 | $207.12 | |
| 84403 | <1% | 14 | $204.38 | |
| 84439 | <1% | 611 | $190.30 | |
| 82105 | <1% | 117 | $164.22 | |
| 96417 | <1% | 20 | $156.42 | |
| J2920 | Injection, methylprednisolone sodium succinate, up to 40 mg | <1% | 62 | $131.03 |
| 99497 | <1% | 137 | $109.26 | |
| 80061 | Lipid panel | <1% | 125 | $99.46 |
| 88291 | <1% | 17 | $93.90 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 90 | $93.57 |
| 86140 | <1% | 252 | $72.63 | |
| 84238 | <1% | 12 | $44.10 | |
| 88381 | <1% | 16 | $43.11 | |
| 84550 | <1% | 582 | $40.68 | |
| 51798 | <1% | 14 | $23.34 | |
| 84100 | <1% | 440 | $22.35 | |
| 84702 | <1% | 15 | $13.18 | |
| 84481 | <1% | 15 | $11.34 | |
| 82248 | <1% | 13 | $5.49 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 29 | $4.69 |
| 80076 | <1% | 31 | $3.04 | |
| 81003 | <1% | 12 | $2.02 | |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation agreement | 0% | 21,762 | $0.00 |
| 85097 | 0% | 13 | $0.00 | |
| 88311 | 0% | 26 | $0.00 | |
| 88341 | 0% | 24 | $0.00 | |
| 81455 | 0% | 65 | $0.00 | |
| 88280 | 0% | 40 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialGORDAN, LUCIO (PRESIDENT/MANAGING PARTNER)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.